Table 1.
Patient characteristics.
| Overall n = 104 |
Patients with Negative LNs n = 43 (41.35%) |
Patients with Positive LNs n = 61 (58.65%) |
|
|---|---|---|---|
| Age, years (median) | 69 | 69 | 68 |
| IQR | 63–72.5 | 63.5–72 | 62–73 |
| Total PSA, ng/mL (median) | 17.21 | 12.77 | 21.79 |
| IQR | 8.32–32.56 | 7.49–24.27 | 11–41.27 |
| No. of LNs removed (median) | 17 | 15 | 17 |
| IQR | 12–21 | 12–20 | 13–21 |
| No. of SLNs removed (median) | 8 | 9 | 7 |
| IQR | 5–11 | 6–12 | 5–11 |
| No. of positive LNs (median) | 2 | ||
| IQR | 1–4 | ||
| Tumor stage (%) | |||
| T1c | 23 (22.12) | 11 (25.58) | 12 (19.67) |
| T2a | 7 (6.73) | 3 (6.98) | 4 (6.56) |
| T2b | 6 (5.77) | 3 (6.98) | 3 (4.92) |
| T2c | 49 (47.12) | 19 (44.19) | 30 (49.18) |
| T3 | 19 (18.27) | 7 (16.28) | 12 (19.67) |
| Biopsy Gleason score (%) | |||
| 6 (3 + 3) | 10 (9.62) | 8 (18.60) | 2 (3.28) |
| 7 (3 + 4) | 25 (24.04) | 11 (25.58) | 14 (22.95) |
| 7 (4 + 3) | 20 (19.23) | 7 (16.28) | 13 (21.31) |
| ≥8 | 49 (47.12) | 17 (39.53) | 32 (52.46) |
| Postoperative Gleason score (%) | |||
| 6 (3 + 3) | 2 (1.94) * | 2 (4.65) | 0 ** |
| 7 (3 + 4) | 23 (22.33) * | 20 (46.51) | 3 (5.00) ** |
| 7 (4 + 3) | 35 (33.98) * | 11 (25.58) | 24 (40.00) ** |
| ≥8 | 43 (41.75) * | 10 (23.26) | 33 (55.00) ** |
| Pathologic stage (%) | |||
| pT2 | 28 (26.92) | 26 (60.47) | 2 (3.28) |
| pT3a | 22 (21.15) | 10 (23.26) | 12 (19.67) |
| pT3b | 50 (48.08) | 7 (16.28) | 43 (70.49) |
| pT4 | 4 (3.85) | 0 | 4 (6.56) |
IQR, Interquartile range; (S)LN, (sentinel) lymph node; PSA, prostate specific antigen; */**, data are based on a population of 103 (*) and 60 (**) patients (respectively), because one patient underwent hormonal treatment prior to radical retropubic prostatectomy, so there was no postoperative Gleason score.